Last reviewed · How we verify

SPEEDA and TRCS SPEEDA — Competitive Intelligence Brief

SPEEDA and TRCS SPEEDA (SPEEDA and TRCS SPEEDA) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Toxicology/Antivenom.

marketed Toxicology/Antivenom Biologic Live · refreshed every 30 min

Target snapshot

SPEEDA and TRCS SPEEDA (SPEEDA and TRCS SPEEDA) — Queen Saovabha Memorial Institute. SPEEDA is a snake venom-derived antivenom or immunobiological therapeutic developed to treat envenomation or related conditions.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
SPEEDA and TRCS SPEEDA TARGET SPEEDA and TRCS SPEEDA Queen Saovabha Memorial Institute marketed

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SPEEDA and TRCS SPEEDA — Competitive Intelligence Brief. https://druglandscape.com/ci/speeda-and-trcs-speeda. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing